Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emideltide
- Development stage
- Unknown
- Modality
- Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
Emideltide, commonly known as delta sleep-inducing peptide (DSIP), is a synthetic nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from the cerebral venous blood of rabbits. It has been studied for its potential to induce slow-wave (delta) sleep and regulate circadian rhythms, as well as for treating opioid withdrawal, chronic insomnia, and narcolepsy. However, human clinical data remains limited and inconsistent, and its exact biological target and mechanism of action are not fully established. In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against recommending emideltide and emideltide acetate for inclusion on the Section 503A Bulks List due to insufficient safety and efficacy data.
- Other names
- DSIPdelta sleep-inducing peptideemideltide acetate
Beyond the preview
Go deeper on emideltide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emideltide.